20,804 Shares in Pfizer Inc. (NYSE:PFE) Purchased by RFG Bristol Wealth Advisors LLC

RFG Bristol Wealth Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,804 shares of the biopharmaceutical company's stock, valued at approximately $552,000.

A number of other institutional investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter valued at $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer in the 4th quarter worth $32,000. Institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PFE. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Price Performance

Shares of PFE traded up $0.19 during mid-day trading on Wednesday, hitting $24.73. 41,783,008 shares of the stock were exchanged, compared to its average volume of 39,243,727. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $140.26 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.33 and a 52-week high of $31.54. The firm has a 50-day moving average of $25.98 and a two-hundred day moving average of $26.83.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Pfizer's revenue was up 24.7% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.